

Ulrich Herrlinger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10238518/publications.pdf>

Version: 2024-02-01

148
papers

8,839
citations

44069

48
h-index

45317

90
g-index

150
all docs

150
docs citations

150
times ranked

9484
citing authors

#	ARTICLE	IF	CITATIONS
1	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1100-1108.	10.7	800
2	High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. <i>Lancet Oncology</i> , The, 2010, 11, 1036-1047.	10.7	530
3	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA09): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 678-688.	13.7	384
4	SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo. <i>Cancer Research</i> , 2004, 64, 7954-7961.	0.9	380
5	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. <i>Lancet Oncology</i> , The, 2015, 16, e322-e332.	10.7	340
6	Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. <i>Journal of Neuro-Oncology</i> , 2005, 72, 169-177.	2.9	335
7	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet</i> , The, 2017, 390, 1645-1653.	13.7	307
8	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2057-2064.	7.0	264
9	Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3357-3361.	1.6	237
10	Vessel Wall Contrast Enhancement: A Diagnostic Sign of Cerebral Vasculitis. <i>Cerebrovascular Diseases</i> , 2008, 26, 23-29.	1.7	199
11	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016, 18, 549-556.	1.2	187
12	NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: Final report. <i>Annals of Neurology</i> , 2005, 57, 843-847.	5.3	181
13	Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. <i>Journal of Neuro-Oncology</i> , 2006, 80, 159-165.	2.9	171
14	German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. <i>Annals of Neurology</i> , 2002, 51, 247-252.	5.3	161
15	Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. <i>Journal of Clinical Oncology</i> , 2006, 24, 4412-4417.	1.6	152
16	Neural Precursor Cells for Delivery of Replication-Conditional HSV-1 Vectors to Intracerebral Gliomas. <i>Molecular Therapy</i> , 2000, 1, 347-357.	8.2	151
17	Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O ⁶ -Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1611-1619.	1.6	151
18	Leptomeningeal metastasis: survival and prognostic factors in 155 patients. <i>Journal of the Neurological Sciences</i> , 2004, 223, 167-178.	0.6	150

#	ARTICLE	IF	CITATIONS
19	Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naïve and bevacizumab-resistant glioblastoma. <i>EMBO Molecular Medicine</i> , 2016, 8, 39-57.	6.9	140
20	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC Tj ETQq0 0 0 rgBT /Overlock 10 Oncology, The, 2021, 22, 813-823.	10.7	132
21	Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide. <i>Journal of Clinical Oncology</i> , 2009, 27, 1257-1261.	1.6	128
22	Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. <i>Annals of Neurology</i> , 2010, 67, 182-189.	5.3	108
23	Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. <i>Clinical Cancer Research</i> , 2016, 22, 2190-2196.	7.0	106
24	Residual tumor cells are unique cellular targets in glioblastoma. <i>Annals of Neurology</i> , 2010, 68, 264-269.	5.3	105
25	Phase II Trial of Temozolomide for Relapsed/Refractory Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1757-1763.	1.6	105
26	Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. <i>Neurology</i> , 2015, 84, 1242-1248.	1.1	94
27	Current status and perspectives of interventional clinical trials for glioblastoma – analysis of ClinicalTrials.gov. <i>Radiation Oncology</i> , 2017, 12, 1.	2.7	87
28	Primary central nervous system lymphoma: from clinical presentation to diagnosis. <i>Journal of Neuro-Oncology</i> , 1999, 43, 219-226.	2.9	84
29	Gliomatosis cerebri: Molecular pathology and clinical course. <i>Annals of Neurology</i> , 2002, 52, 390-399.	5.3	83
30	Targeting the Cytosolic Innate Immune Receptors RIG-I and MDA5 Effectively Counteracts Cancer Cell Heterogeneity in Glioblastoma. <i>Stem Cells</i> , 2013, 31, 1064-1074.	3.2	76
31	Gliomatosis cerebri: no evidence for a separate brain tumor entity. <i>Acta Neuropathologica</i> , 2016, 131, 309-319.	7.7	74
32	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. <i>Cancer Immunology Research</i> , 2019, 7, 1910-1927.	3.4	74
33	Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. <i>Journal of Neuro-Oncology</i> , 2010, 97, 389-392.	2.9	72
34	New Prodrug Activation Gene Therapy for Cancer Using Cytochrome P450 4B1 and 2-Aminoanthracene/4-Ipomeanol. <i>Human Gene Therapy</i> , 1998, 9, 1261-1273.	2.7	69
35	Long-Term Survival in a Rodent Model of Disseminated Brain Tumors by Combined Intrathecal Delivery of Herpes Vectors and Ganciclovir Treatment. <i>Human Gene Therapy</i> , 1996, 7, 1989-1994.	2.7	66
36	Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. <i>Journal of Neuro-Oncology</i> , 2014, 117, 337-345.	2.9	66

#	ARTICLE	IF	CITATIONS
37	Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. <i>Neuro-Oncology</i> , 2016, 18, 1462-1464.	1.2	65
38	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. <i>Neuro-Oncology</i> , 2018, 20, 1616-1624.	1.2	65
39	Imaging-Guided Gene Therapy of Experimental Gliomas. <i>Cancer Research</i> , 2007, 67, 1706-1715.	0.9	62
40	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , 2021, 23, 1100-1112.	1.2	59
41	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). <i>Neuro-Oncology</i> , 2014, 16, 92-102.	1.2	57
42	Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1815-1821.	2.5	57
43	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). <i>Neuro-Oncology</i> , 2018, 20, 400-410.	1.2	56
44	Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma. <i>Oncotarget</i> , 2017, 8, 8294-8304.	1.8	55
45	Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. <i>Biochemical and Biophysical Research Communications</i> , 2005, 328, 125-129.	2.1	54
46	Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. <i>Neurology</i> , 2017, 88, 1422-1430.	1.1	54
47	Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors. <i>Journal of Translational Medicine</i> , 2019, 17, 96.	4.4	54
48	Low-grade primary central nervous system lymphoma in immunocompetent patients. <i>British Journal of Haematology</i> , 2005, 128, 616-624.	2.5	53
49	Intraarterial Delivery of Adenovirus Vectors and Liposome-DNA Complexes to Experimental Brain Neoplasms. <i>Human Gene Therapy</i> , 1999, 10, 311-318.	2.7	51
50	Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide. <i>Journal of Clinical Oncology</i> , 2012, 30, e180-e183.	1.6	49
51	Primary central nervous system lymphoma 1991-1997. <i>Cancer</i> , 2001, 91, 130-135.	4.1	46
52	Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. <i>Oncology Reports</i> , 2017, 38, 3291-3296.	2.6	46
53	Primary CNS lymphoma: findings outside the brain. , 1999, 43, 227-230.		45
54	Quantitative T1â€œmapping detects cloudyâ€œenhancing tumor compartments predicting outcome of patients with glioblastoma. <i>Cancer Medicine</i> , 2017, 6, 89-99.	2.8	44

#	ARTICLE	IF	CITATIONS
55	Disconnecting multicellular networks in brain tumours. <i>Nature Reviews Cancer</i> , 2022, 22, 481-491.	28.4	44
56	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. <i>Neuro-Oncology</i> , 2020, 22, 1162-1172.	1.2	42
57	New aspects of immunotherapy of leptomeningeal metastasis. <i>Journal of Neuro-Oncology</i> , 1998, 38, 233-239.	2.9	39
58	UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2005, 71, 295-299.	2.9	35
59	Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. <i>BMC Cancer</i> , 2020, 20, 355.	2.6	33
60	Health-related quality of life and neurocognitive functioning with lomustine vs temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1444-1453.	10.7	29
61	Diffusion Abnormality in Balo's Concentric Sclerosis: Clues for the Pathogenesis. <i>European Neurology</i> , 2005, 53, 42-44.	1.4	26
62	Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 787-792.	2.5	26
63	Effect of early palliative care for patients with glioblastoma (EPCOG): a randomised phase III clinical trial protocol. <i>BMJ Open</i> , 2020, 10, e034378.	1.9	26
64	Very late relapses in glioblastoma long-term survivors. <i>Journal of Neurology</i> , 2009, 256, 1756-1758.	3.6	25
65	A Preliminary Study on Machine Learning-Based Evaluation of Static and Dynamic FET-PET for the Detection of Pseudoprogression in Patients with IDH-Wildtype Glioblastoma. <i>Cancers</i> , 2020, 12, 3080.	3.7	25
66	Early treatment response assessment using ¹⁸ F-FET PET compared to contrast-enhanced MRI in glioma patients following adjuvant temozolomide chemotherapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.254243.	5.0	25
67	Targeting gene therapy vectors to CNS malignancies. <i>Journal of NeuroVirology</i> , 1998, 4, 133-147.	2.1	23
68	Surgery for temporal glioblastoma: lobectomy outranks oncosurgical-based gross-total resection. <i>Journal of Neuro-Oncology</i> , 2019, 145, 143-150.	2.9	23
69	Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma. <i>Neuro-Oncology</i> , 2021, 23, 1885-1897.	1.2	23
70	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019, 116, 190-198.	2.8	22
71	Comorbidity Burden and Presence of Multiple Intracranial Lesions Are Associated with Adverse Events after Surgical Treatment of Patients with Brain Metastases. <i>Cancers</i> , 2020, 12, 3209.	3.7	21
72	The Colony Stimulating Factor-1 Receptor (CSF-1R)-Mediated Regulation of Microglia/Macrophages as a Target for Neurological Disorders (Glioma, Stroke). <i>Frontiers in Immunology</i> , 2021, 12, 787307.	4.8	21

#	ARTICLE	IF	CITATIONS
73	HSV-1 infected cell proteins influence tetracycline-regulated transgene expression. <i>Journal of Gene Medicine</i> , 2000, 2, 379-389.	2.8	20
74	Inhibition of Gap Junctions Sensitizes Primary Glioblastoma Cells for Temozolomide. <i>Cancers</i> , 2019, 11, 858.	3.7	20
75	Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey. <i>Journal of Neuro-Oncology</i> , 2021, 153, 479-485.	2.9	20
76	Newly diagnosed glioblastoma in geriatric (65+ years) patients: impact of patients frailty, comorbidity burden and obesity on overall survival. <i>Journal of Neuro-Oncology</i> , 2020, 149, 421-427.	2.9	20
77	Should Intra-cerebrospinal Fluid Prophylaxis Be Part of Initial Therapy for Patients With Non-Hodgkin Lymphoma: What We Know, and How We Can Find Out More. <i>Seminars in Oncology</i> , 2009, 36, S25-S34.	2.2	19
78	Diagnosis of Pseudoprogression Following Lomustine+Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. <i>Clinical Cancer Research</i> , 2021, 27, 3704-3713.	7.0	19
79	Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma. <i>Neurology</i> , 2020, 95, e3138-e3144.	1.1	18
80	Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 1742-1756.	1.2	18
81	Combined Assessment of Preoperative Frailty and Sarcopenia Allows the Prediction of Overall Survival in Patients with Lung Cancer (NSCLC) and Surgically Treated Brain Metastasis. <i>Cancers</i> , 2021, 13, 3353.	3.7	18
82	ACTR-58. PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial. <i>Neuro-Oncology</i> , 2017, 19, vi13-vi14.	1.2	17
83	Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7211.	4.1	17
84	Safety metric profiling in surgery for temporal glioblastoma: lobectomy as a supra-total resection regime preserves perioperative standard quality rates. <i>Journal of Neuro-Oncology</i> , 2020, 149, 455-461.	2.9	16
85	Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis. <i>Neuro-Oncology</i> , 2019, 21, 954-955.	1.2	15
86	Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12. <i>Cancers</i> , 2019, 11, 272.	3.7	15
87	PDGFRFB mutation-associated myofibromatosis: Response to targeted therapy with imatinib. <i>American Journal of Medical Genetics, Part A</i> , 2019, 179, 1895-1897.	1.2	14
88	Baseline Serum C-Reactive Protein and Plasma Fibrinogen-Based Score in the Prediction of Survival in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 653614.	2.8	14
89	Outcome of Elderly Patients With Surgically Treated Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 713965.	2.8	14
90	MIP-1 Antagonizes the Effect of a GM-CSF-Enhanced Subcutaneous Vaccine in a Mouse Glioma Model. <i>Journal of Neuro-Oncology</i> , 2004, 66, 147-154.	2.9	13

#	ARTICLE	IF	CITATIONS
91	Extracellular Vesicle Separation Techniques Impact Results from Human Blood Samples: Considerations for Diagnostic Applications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9211.	4.1	13
92	Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 117-130.	2.9	12
93	Seizure outcome in temporal glioblastoma surgery: lobectomy as a supratotal resection regime outclasses conventional gross-total resection. <i>Journal of Neuro-Oncology</i> , 2021, 152, 339-346.	2.9	12
94	Prognostic Value of Preoperative Inflammatory Markers in Melanoma Patients with Brain Metastases. <i>Journal of Clinical Medicine</i> , 2021, 10, 634.	2.4	12
95	Intrathecal treatment of C6 glioma leptomeningeal metastasis in Wistar rats with interleukin-2. <i>Journal of Neuro-Oncology</i> , 1996, 27, 193-203.	2.9	11
96	Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 975-985.	1.2	11
97	Impact of initial midline shift in glioblastoma on survival. <i>Neurosurgical Review</i> , 2021, 44, 1401-1409.	2.4	11
98	MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial. <i>International Journal of Cancer</i> , 2021, 148, 1695-1707.	5.1	11
99	Machine learning-based differentiation between multiple sclerosis and glioma WHO II ^o -IV ^o using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography. <i>Journal of Neuro-Oncology</i> , 2021, 152, 325-332.	2.9	11
100	Preoperative Metastatic Brain Tumor-Associated Intracerebral Hemorrhage Is Associated With Dismal Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 699860.	2.8	11
101	Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients. <i>Journal of Clinical Oncology</i> , 2014, 32, 2042-2042.	1.6	11
102	Benchmarking Safety Indicators of Surgical Treatment of Brain Metastases Combined with Intraoperative Radiotherapy: Results of Prospective Observational Study with Comparative Matched-Pair Analysis. <i>Cancers</i> , 2022, 14, 1515.	3.7	11
103	Treosulfan chemotherapy for recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2000, 49, 231-234.	2.9	10
104	Gliomatosis cerebri. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 507-515.	1.8	10
105	The Impact of Prolonged Mechanical Ventilation on Overall Survival in Patients With Surgically Treated Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 658949.	2.8	10
106	FORGE: A Novel Scoring System to Predict the MIB-1 Labeling Index in Intracranial Meningiomas. <i>Cancers</i> , 2021, 13, 3643.	3.7	10
107	Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial. <i>Trials</i> , 2022, 23, 57.	1.6	10
108	Outcome of Tumor-Associated Proptosis in Patients With Spheno-Orbital Meningioma: Single-Center Experience and Systematic Review of the Literature. <i>Frontiers in Oncology</i> , 2020, 10, 574074.	2.8	9

#	ARTICLE	IF	CITATIONS
109	Postoperative Prolonged Mechanical Ventilation in Patients With Newly Diagnosed Glioblastoma—An Unrecognized Prognostic Factor. <i>Frontiers in Oncology</i> , 2020, 10, 607557.	2.8	9
110	The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. <i>Neuro-Oncology</i> , 2021, 23, 2076-2084.	1.2	9
111	Proliferative Potential, and Inflammatory Tumor Microenvironment in Meningioma Correlate with Neurological Function at Presentation and Anatomical Location—From Convexity to Skull Base and Spine. <i>Cancers</i> , 2022, 14, 1033.	3.7	9
112	Red blood cell distribution width to platelet ratio substantiates preoperative survival prediction in patients with newly-diagnosed glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 154, 229-235.	2.9	8
113	Longitudinal, leakage corrected and uncorrected rCBV during the first-line treatment of glioblastoma: a prospective study. <i>Journal of Neuro-Oncology</i> , 2019, 144, 409-417.	2.9	7
114	Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status. <i>Pharmaceuticals</i> , 2021, 14, 195.	3.8	7
115	Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 759873.	2.8	7
116	Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 695316.	2.8	6
117	MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2015-2015.	1.6	6
118	Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin. <i>Journal of Neuro-Oncology</i> , 1998, 40, 1-9.	2.9	5
119	A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center. <i>BMC Cancer</i> , 2019, 19, 1024.	2.6	5
120	No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany. <i>BMC Cancer</i> , 2021, 21, 526.	2.6	3
121	Perioperative red blood cell transfusion is associated with poor functional outcome and overall survival in patients with newly diagnosed glioblastoma. <i>Neurosurgical Review</i> , 2022, 45, 1327-1333.	2.4	3
122	ACKT: A Proposal for a Novel Score to Predict Prolonged Mechanical Ventilation after Surgical Treatment of Meningioma in Geriatric Patients. <i>Cancers</i> , 2021, 13, 98.	3.7	3
123	Inflammatory Tumor Microenvironment in Cranial Meningiomas: Clinical Implications and Intraindividual Reproducibility. <i>Diagnostics</i> , 2022, 12, 853.	2.6	3
124	NIMG-79. EARLY TREATMENT RESPONSE ASSESSMENT USING O-(2-18F-FLUOROETHYL)-L-TYROSINE (FET) PET COMPARED TO MRI IN MALIGNANT GLIOMAS TREATED WITH ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi193-vi193.	1.2	2
125	Corticosteroid-responsive aseptic meningitis during regorafenib treatment. <i>Neuro-Oncology Practice</i> , 2019, 6, 508-509.	1.6	2
126	Tumor-associated epilepsy in patients with brain metastases: necrosis-to-tumor ratio forecasts postoperative seizure freedom. <i>Neurosurgical Review</i> , 2022, 45, 545-551.	2.4	2

#	ARTICLE	IF	CITATIONS
127	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. <i>Neurology</i> , 2022, 98, .	1.1	2
128	Chasing a Rarity: A Retrospective single-center evaluation of prognostic factors in primary gliosarcoma. <i>Strahlentherapie Und Onkologie</i> , 2021, , 1.	2.0	2
129	Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma. <i>Journal of Clinical Neuroscience</i> , 2018, 53, 255-258.	1.5	1
130	News on the horizon in glioblastoma therapy. <i>ESMO Open</i> , 2020, 5, e000601.	4.5	1
131	Chemotherapy for adult patients with spinal cord gliomas. <i>Neuro-Oncology Practice</i> , 2021, 8, 475-484.	1.6	1
132	The Surgical Management of Brain Metastases in Non-Small Cell Lung Cancer (NSCLC): Identification of the Early Laboratory and Clinical Determinants of Survival. <i>Journal of Clinical Medicine</i> , 2021, 10, 4013.	2.4	1
133	Impact of Levetiracetam Treatment on 5-Aminolevulinic Acid Fluorescence Expression in IDH1 Wild-Type Glioblastoma. <i>Cancers</i> , 2022, 14, 2134.	3.7	1
134	Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. <i>Journal of Neuro-Oncology</i> , 0, , .	2.9	1
135	Radiotherapy and olaptesed pegol (NOX-A12) in partially resected or biopsy-only MGMT-unmethylated glioblastoma: Interim data from the German multicenter phase 1/2 GLORIA trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2050-2050.	1.6	1
136	NIMG-40MRI TUMOR PROGRESSION PATTERNS IN THE GLARIUS TRIAL. <i>Neuro-Oncology</i> , 2015, 17, v162.4-v163.	1.2	0
137	NIMG-41MRI FINDINGS IN THE GLARIUS TRIAL: PROGNOSTIC AND PREDICTIVE IMPLICATIONS. <i>Neuro-Oncology</i> , 2015, 17, v163.1-v163.	1.2	0
138	QOLP-29. SYMPTOM CLUSTERS IN NEWLY DIAGNOSED GLIOMA PATIENTS: WHICH CLUSTERS ARE ASSOCIATED WITH FUNCTIONING AND GLOBAL HEALTH STATUS?. <i>Neuro-Oncology</i> , 2018, 20, vi221-vi221.	1.2	0
139	ACTR-64. OBJECTIVE RESPONSES TO CHEMOTHERAPY IN RECURRENT GLIOMA DO NOT PREDICT BETTER SURVIVAL: A PROSPECTIVE ANALYSIS FROM THE GERMAN GLIOMA NETWORK. <i>Neuro-Oncology</i> , 2018, 20, vi26-vi26.	1.2	0
140	Treatment of metastasized melanoma with combined checkpoint inhibition in a patient with highly active multiple sclerosis. <i>Journal of Dermatology</i> , 2020, 47, e184-e185.	1.2	0
141	Prognostic factors in leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021, 23, 1208-1209.	1.2	0
142	Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS2103-TPS2103.	1.6	0
143	<i>Neuroonkologie.</i> , 2020, , 257-271.		0
144	BIOM-08. DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021, 23, vi11-vi11.	1.2	0

#	ARTICLE	IF	CITATIONS
145	BIOM-24. PROTEIN SURFACE SIGNATURE ON SERUM EXTRACELLULAR VESICLES FOR NON-INVASIVE DETECTION OF TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS. <i>Neuro-Oncology</i> , 2021, 23, vi15-vi16.	1.2	0
146	NIMG-26. DIAGNOSIS OF PSEUDOPROGRESSION FOLLOWING RADIOTHERAPY PLUS LOMUSTINE-TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS USING FET PET. <i>Neuro-Oncology</i> , 2020, 22, ii152-ii153.	1.2	0
147	NIMG-14. MACHINE LEARNING-BASED EVALUATION OF STATIC AND DYNAMIC FET-PET FOR THE DETECTION OF PSEUDOPROGRESSION IN PATIENTS WITH IDH-WILDTYPE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii149-ii150.	1.2	0
148	BIOM-40. ANALYSIS OF SERUM MIRNA IN GLIOBLASTOMA PATIENTS: TARGETED ENRICHMENT OF EXTRACELLULAR VESICLES ENHANCES SPECIFICITY FOR PROGNOSTIC SIGNATURE. <i>Neuro-Oncology</i> , 2020, 22, ii10-ii10.	1.2	0